Want to see PCVX full AI Analyst Report?
PCVX Stock Chart & Stats
$62.35
-$2.14(-2.45%)
At close: 4:00 PM EST
$62.35
-$2.14(-2.45%)
Day’s Range― - ―
52-Week Range$29.08 - $65.00
Previous CloseN/A
Volume105.48K
Average Volume (3M)1.71M
Market Cap
$8.41B
Enterprise Value$7.17B
Total Cash (Recent Filing)$1.74B
Total Debt (Recent Filing)$116.30M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Aug 12, 2026EPS Estimate
-2.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.89
Shares Outstanding144,397,670
10 Day Avg. Volume1,438,353
30 Day Avg. Volume1,713,882
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio-9.38
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.23K
Enterprise Value/Ebitda-7.79
Forecast
1Y Price Target
$116.00Price Target Upside86.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-8.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetA sizable equity base and low debt provide durable financial flexibility to fund costly clinical programs and manufacturing scale-up. This reduces near-term insolvency risk, supports strategic optionality (licensing, partners), and lengthens runway versus high-leverage peers.
Experienced Board And Governance ContinuityAdding vaccine and manufacturing expertise to the board and re-electing key directors strengthens strategic oversight and regulatory navigation. Improved governance and continuity support higher-probability execution of complex clinical and supply initiatives, lowering program execution risk.
Focused Pneumococcal Vaccine PipelineA clear, specialty pipeline targeting pneumococcal disease aligns with durable global vaccine demand and creates potential differentiation if higher-valency candidates show superiority. Focused R&D can concentrate resources, improving odds of advancing lead programs to pivotal stages.
Bears Say
Zero RevenueWithout product revenue, the company must rely on external financing and partnerships to sustain operations. This structural lack of recurring cash inflows increases capital markets dependence and elevates execution risk if clinical timelines slip or approvals are delayed.
Rapidly Escalating Cash BurnSteep and rising cash consumption materially shortens the cash runway absent new financing or sizable collaboration monetization. Persistent negative free cash flow forces program prioritization, can delay launches, and raises dilution or covenant risks for the medium term.
Negative Returns On Capital And Financing RelianceA strongly negative ROE shows current capital is producing losses, not returns. Continued dependence on equity and partner funding risks shareholder dilution and may constrain long-term strategic investments if future fundraises are costly or partners demand concessions.
Vaxcyte News
PCVX FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was $29.08 and its highest was $65.00 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Vaxcyte, Inc.’s market cap is $8.41B.
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 30 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on May 06, 2026. The company reported -$2.3 earnings per share for the quarter, missing the consensus estimate of -$1.778 by -$0.522.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -2.06.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 144,397,670 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -$2.3 in its last earnings report, missing expectations of -$1.778. Following the earnings report the stock price went down -9.842%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Currently, no hedge funds are holding shares in PCVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vaxcyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$116.00 (86.05% Upside)
$116.00 (86.05% Upside)
Blogger Sentiment
Bullish
PCVX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.62%
12-Months-Change
Fundamentals
Return on Equity
-32.51%
Trailing 12-Months
Asset Growth
-0.88%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
PCVX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strongly positive operational and clinical momentum story: robust balance sheet extended by a ~$600M financing, completion of a commercial-scale manufacturing facility on time and on budget, initiation of three pivotal/Phase III adult OPUS trials with expected top-line readouts over the next 18 months, completed infant enrollment (900 infants), and resumption of the Group A Strep program. Offsetting risks are mostly predictable near-term impacts from materially higher R&D and manufacturing expenses in 2026, serotype-level regulatory uncertainties (and the idiosyncratic challenge of serotype 3), and a competitive landscape with other PCV developers. Overall, the highlights—particularly cash runway, manufacturing completion, and late-stage clinical progress—materially outweigh the lowlights, which are manageable programmatic and financial execution risks.View all PCVX earnings summariesPCVX Stock 12 Month Forecast
Average Price Target
$116.00
▲(86.05% Upside)
Technical Analysis
Ownership Overview
0.76% Insiders
39.37% Mutual Funds
0.12% Other Institutional Investors
42.15% Public Companies and
Individual Investors